MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: Relationships to drug exposure, p53 mutations, and clinical outcome of the patients

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3575-3581

  Lizard Nacol, Sarab ^a,f   Genne, Philippe ^d   Coudert, Bruno ^b   Riedinger, Jean Marc ^c   Arnal, Muriel ^a   Sancy, Celine ^a   Brunet Lecomte, Patrick ^e   Fargeot, Pierre ^b  

^a INSERM   (France)

^b Oncological Service   (France)

^c Laboratory of Medical Biology   (France)

^d Oncodesign   (France)

^e HÔPITAL DU BOCAGE   (France)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Advanced breast cancer; MDRI and TS genes expression; p53 mutations; RT PCR

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MUTANT PROTEIN; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0033458682     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In: Cancer: principles and practice of oncology (DeVita VT Jr, Hellman S, Rosenberg SA, eds). Philadelphia; Lippincott, 1993, pp 1264-1332.
2. Goldstein LJ: MDR1 gene expression in solid tumours. Eur J Cancer 32A: 1039-1050, 1996.
3. Gros P, Croop J, Housman D: Mammalian multidrug-resistance gene: complete sequence indicates strong homology to bacterial transport proteins. Cell 47: 371-374, 1986.
4. Giaccone G, Linn SC, Pinedo HM: Multidrug resistance in breast cancer: mechanisms, strategies. Eurp J Cancer 31A, Suppl. 7: S15-S17, 1995.
5. Radvin PM: Anthracycline resistance in breast cancer: clinical applications of current knowledge. Eu J Cancer 31A: S11-S14, 1995.
6. Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfied SS, Hill W, Kates R: Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4: 1451-1457, 1998.
7. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931, 1997.
8. Kaye SB: Multidrug resistance in breast cancer. Is the jury in yet? J Nat. Cancer Inst 89: 902-903, 1997.
9. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by p-glycoprotein staining. J Natl Cancer Inst 81: 696-701, 1989.
10. Chevillard S, Pouillart P, Beljord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292-300, 1996.
11. Linn SC, Pinedo HM, Van Ark-Otte J, Van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71: 787-795, 1997.
12. Wang CS, LaRue H, Fortin A, Gariepy G, Tetu B: mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res Treat 45: 63-74, 1997.
13. Punyammlee B, Manoromana S, Purisa W, Chariyalertsak S, Rerkamnuaychok B: Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer. J Med Assoc Thai 80SI: S162-S173, 1997.
14. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruchaud JP: Levels of multidrug resistance (MDRI) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998.
15. Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA, Yeh GC, Allegra CJ: Induction of thymidylate synthase associated with miltidrug resistance in human breast and colon cancer cell lines. Mol Pharm 39: 136-143, 1990.
16. Chu DM, and Allegra CJ: The role of thymidylate synthase in cellular regulation. Advantages of Enzyme Regulation 36: 143-163, 1996.
17. Larsson PA, Carlsson G, Gustavsson B, Spears CP: Thymidylate synthase in advanced gastrointestinal and breast cancers. Acta Oncol 35: 469-472, 1996.
18. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouf R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ, Johnston PG: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931, 1997.
19. Lonn U, Lonn S, Nilsson B, Stenkvist B: Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Cancer 77: 107-112, 1996.
20. Elledge RM, Okuyama N, Fitzgerald SD, Fugua SA: Evaluation of thymidylate synthase RNA expression by polymerase chain reaction. Mol Cell Probes 8: 67-72, 1994.
21. Vogelstein B, and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
22. Lowe SW, Ruley HE, Jacks T, Housman D: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
23. Chin K V, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the human MDR1 gene by Ras and p53. Science 255: 459-462, 1992.
24. Strauss BE, and Haas M: The region 3' to the major transcriptional start site of the MDRI downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun 217: 333-340, 1995.
25. Strauss BE, Shivakumar C, Deb SP, Haas M: The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun 217: 825-831, 1995.
26. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD: p53-dependent regulation of MDRI gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94: 11037-11042, 1997.
27. Li ZH, Zhu YJ, Lit XT: Wild-type p53 gene increases MDR1 gene expression dut decreases drug resistance in a MDR cell line KBV200. Cancer Lett 119: 177-184, 1997.
28. Zhou G, and Tien Kuo M: Wild-type p53-mediated induction of rat mdrlb expression by the anticancer drug daunoruhicin. J Biol Chem 273: 15387-15394, 1997.
29. Lee Y, Chen Y, Chang LS, Johson LF: Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 234: 270-276, 1997.
30. Chomczynski P, and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochm 162: 156-159, 1987.
31. Lizard-Nacol S, Coudert B, Riedinger JM, Fargeot P, Guerrin J: p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemetherapy in human breast cancer. Int J Oncol 10: 1203-1207, 1997.
32. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton, JC, Goldstein LJ: Qantitative reverse trascriptase- polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin.Cancer Res 4: 1533-1542, 1948.
33. Preudhomme C, Lepelley P, Vachee A, Soenen V, Quesnel B, Cosson A, Fenaux, P Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia 7: 1888-1890, 1993.
34. De Angelis P, Stokke T, Sumedshammer L, Lothe RA, Lehne G, Cen Y, Clausen OP: P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 72: 307-311, 1945.
35. de Kant E, Heide I, Thiede C, Herrmann R, Rochlitz CF: MDR1 expression correlates with mutant p53 in colorectal cancer metastases. J Cancer Res Clin Oncol 122: 671-675, 1996.
36. Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, Ikeda K, Tsurutani J, Ikuno N, Omagari K, Mizuta Y, Soda H, Gudas JM, Kohno S: P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 88: 738-742, 1997.
37. Linn SC, Honkoop AH, Hoekman K, Van der Valk P, Pinedo HM, Giaccone G: p53 and p- glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74: 63-68, 1996.
38. Bodey B, Bodey B Jr., Groger AM, Luck JV, Siegel SE, Taylor C, Kaiser H: Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance. Anticancer Res 17: 1311-1318, 1997.
39. Chevillard S, Lebeau J, Pouillart P, de Toma C, Beljord C, Asselain B, Klijanienko J, Fourquet A, Magdelenat H, Vielh P: Biological and clinical significance of concurrent p53 gene alterations, MDRI gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3: 2471-2478, 1997.
40. Lenz H J, Dannenherg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Dannenberg PV, Leichman LP: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4: 1227-1234, 1998.